after agreeing to take part, you sign a consent form that explains the study in simple language.

your eligibility for the study is confirmed at this point.

a series of measurements are taken before any medication is given, including blood tests for hemoglobin a1c, weight, and other health checks.

the results are recorded as the baseline values that will be compared with later results.

you are assigned, by a computer system, to receive either tirzepatide or a matching placebo without knowing which one you receive.

a study staff member shows you how to use the pre‑filled pen for a subcutaneous injection (injection under the skin).

you practice the technique until you feel comfortable performing the injection yourself.

you begin giving yourself an injection once each week.

the medication is tirzepatide for those assigned to the active group, or a matching placebo for the control group.

the exact dose is set by the study protocol and is delivered using the pre‑filled pen.

this weekly schedule continues for the full study period, which lasts until week 40.

you attend visits at the study site roughly every four weeks.

during each visit, blood samples are taken to check hemoglobin a1c and other safety parameters.

any side effects or concerns are reviewed, and the study team confirms that the weekly injections are being taken as planned.

at the end of week 40, a comprehensive set of measurements is repeated, including the primary endpoint of change in hemoglobin a1c from the baseline value.

the study medication is stopped after this final assessment.

after the final visit, you are no longer required to follow the study schedule.

the study team may discuss any further follow‑up that is needed for your health.